(RTTNews) – Teleflex Incorporated (TFX) has launched the UroLift System in Japan for the treatment of benign prostatic hyperplasia, or enlarged prostate. It is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia. The company previously announced reimbursement approval from the Central Social Insurance Medical Council of Japan. In Japan, the UroLift system is indicated for patients with difficulty urinating associated with benign prostatic hyperplasia.
Liam Kelly, CEO of Teleflex, said, “As we execute our overseas expansion strategy for the UroLift system, Japan represents an important step in our progress.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.